FDA approves Theravance's lung drug for wider use

June 21, 2013 10:18 PM

12 0

FDA approves Theravance's lung drug for wider use

(Reuters) - The U.S. Food and Drug Administration approved Theravance Inc's antibiotic lung drug to treat a type of bacterial pneumonia affecting hospitalized patients, particularly those on ventilators.

The drug, Vibativ, will reach the market in the third quarter of 2013 for its expanded use. The drug is already approved in the United States and Canada to treat bacterial skin infections.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...